Literature DB >> 26065371

Verification Benchmarks to Assess the Implementation of Computational Fluid Dynamics Based Hemolysis Prediction Models.

Prasanna Hariharan, Gavin D'Souza, Marc Horner, Richard A Malinauskas, Matthew R Myers.   

Abstract

As part of an ongoing effort to develop verification and validation (V&V) standards for using computational fluid dynamics (CFD) in the evaluation of medical devices, we have developed idealized flow-based verification benchmarks to assess the implementation of commonly cited power-law based hemolysis models in CFD. Verification process ensures that all governing equations are solved correctly and the model is free of user and numerical errors. To perform verification for power-law based hemolysis modeling, analytical solutions for the Eulerian power-law blood damage model (which estimates hemolysis index (HI) as a function of shear stress and exposure time) were obtained for Couette and inclined Couette flow models, and for Newtonian and non-Newtonian pipe flow models. Subsequently, CFD simulations of fluid flow and HI were performed using Eulerian and three different Lagrangian-based hemolysis models and compared with the analytical solutions. For all the geometries, the blood damage results from the Eulerian-based CFD simulations matched the Eulerian analytical solutions within ∼1%, which indicates successful implementation of the Eulerian hemolysis model. Agreement between the Lagrangian and Eulerian models depended upon the choice of the hemolysis power-law constants. For the commonly used values of power-law constants (α  = 1.9-2.42 and β  = 0.65-0.80), in the absence of flow acceleration, most of the Lagrangian models matched the Eulerian results within 5%. In the presence of flow acceleration (inclined Couette flow), moderate differences (∼10%) were observed between the Lagrangian and Eulerian models. This difference increased to greater than 100% as the beta exponent decreased. These simplified flow problems can be used as standard benchmarks for verifying the implementation of blood damage predictive models in commercial and open-source CFD codes. The current study only used power-law model as an illustrative example to emphasize the need for model verification. Similar verification problems could be developed for other types of hemolysis models (such as strain-based and energy dissipation-based methods). However, since the current study did not include experimental validation, the results from the verified models do not guarantee accurate hemolysis predictions. This verification step must be followed by experimental validation before the hemolysis models can be used for actual device safety evaluations.

Entities:  

Mesh:

Year:  2015        PMID: 26065371     DOI: 10.1115/1.4030823

Source DB:  PubMed          Journal:  J Biomech Eng        ISSN: 0148-0731            Impact factor:   2.097


  3 in total

1.  Assessing Computational Model Credibility Using a Risk-Based Framework: Application to Hemolysis in Centrifugal Blood Pumps.

Authors:  Tina M Morrison; Prasanna Hariharan; Chloe M Funkhouser; Payman Afshari; Mark Goodin; Marc Horner
Journal:  ASAIO J       Date:  2019 May/Jun       Impact factor: 2.872

2.  Computations of the shear stresses distribution experienced by passive particles as they circulate in turbulent flow: A case study for vWF protein molecules.

Authors:  Oanh L Pham; Samuel E Feher; Quoc T Nguyen; Dimitrios V Papavassiliou
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

3.  Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.

Authors:  Flora T Musuamba; Ine Skottheim Rusten; Raphaëlle Lesage; Giulia Russo; Roberta Bursi; Luca Emili; Gaby Wangorsch; Efthymios Manolis; Kristin E Karlsson; Alexander Kulesza; Eulalie Courcelles; Jean-Pierre Boissel; Cécile F Rousseau; Emmanuelle M Voisin; Rossana Alessandrello; Nuno Curado; Enrico Dall'ara; Blanca Rodriguez; Francesco Pappalardo; Liesbet Geris
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.